[go: up one dir, main page]

MX2018002612A - Composicion farmaceutica para tumor que tiene mutacion de isocitrato deshidrogenada, agente antitumoral y uso del mismo. - Google Patents

Composicion farmaceutica para tumor que tiene mutacion de isocitrato deshidrogenada, agente antitumoral y uso del mismo.

Info

Publication number
MX2018002612A
MX2018002612A MX2018002612A MX2018002612A MX2018002612A MX 2018002612 A MX2018002612 A MX 2018002612A MX 2018002612 A MX2018002612 A MX 2018002612A MX 2018002612 A MX2018002612 A MX 2018002612A MX 2018002612 A MX2018002612 A MX 2018002612A
Authority
MX
Mexico
Prior art keywords
pharmaceutical composition
tumor
isocitrate dehydrogenase
antitumor agent
dehydrogenase mutation
Prior art date
Application number
MX2018002612A
Other languages
English (en)
Inventor
Janku Filip
Yamada Takayuki
Original Assignee
Fujifilm Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujifilm Corp filed Critical Fujifilm Corp
Publication of MX2018002612A publication Critical patent/MX2018002612A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a una composición farmacéutica y un agente antitumoral que presenta efectos en el tumor que tiene mutación de isocitrato deshidrogenasa. De conformidad con la presente invención, se proporciona una composición farmacéutica para tratar tumor que tiene mutación de isocitrato deshidrogenasa, que comprende 1- (2-desoxi-2-fluoro-4-tio-ß-D-arab inofuranosil) citosina, una sal de la misma, o un profármaco de la misma.
MX2018002612A 2018-01-29 2018-03-01 Composicion farmaceutica para tumor que tiene mutacion de isocitrato deshidrogenada, agente antitumoral y uso del mismo. MX2018002612A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862623293P 2018-01-29 2018-01-29

Publications (1)

Publication Number Publication Date
MX2018002612A true MX2018002612A (es) 2019-07-30

Family

ID=67394899

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018002612A MX2018002612A (es) 2018-01-29 2018-03-01 Composicion farmaceutica para tumor que tiene mutacion de isocitrato deshidrogenada, agente antitumoral y uso del mismo.

Country Status (3)

Country Link
MX (1) MX2018002612A (es)
TW (1) TW201932120A (es)
WO (1) WO2019146129A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023008511A1 (ja) 2021-07-29 2023-02-02 富士フイルム株式会社 Ｂａｐ１およびｐｂｒｍ１の少なくとも１つの機能低下を有する腫瘍に対する医薬組成物および抗腫瘍剤

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2224155C (en) * 1996-04-09 2004-10-26 Yamasa Corporation 1-(2-deoxy-2-fluoro-4-thio-beta-d-arabinofuranosyl)cytosine
SMT202000275T1 (it) * 2014-10-01 2020-07-08 Daiichi Sankyo Co Ltd Derivato isossazolico come inibitore dell'isocitrato deidrogenasi 1 mutata
CN107428690B (zh) * 2014-12-22 2021-04-13 美国政府健康及人类服务部 可用于治疗癌症的突变idh1抑制剂

Also Published As

Publication number Publication date
TW201932120A (zh) 2019-08-16
WO2019146129A1 (ja) 2019-08-01

Similar Documents

Publication Publication Date Title
PH12020551760A1 (en) Pyridazinones as parp7 inhibitors
PH12022551013A1 (en) Pyridazinones as parp7 inhibitors
PH12018502102A1 (en) Pyrrolotriazine compounds as tam inhibitors
PH12018500642A1 (en) Anti-garp antibody
EA033395B1 (ru) Ингибиторы индоламин-2,3-диоксигеназы и способы их применения
AU2016256469A8 (en) Methods for treating cancer
PH12015502028A1 (en) Ido inhibitors
MX366875B (es) Inhibidores de indoleamina 2,3-dioxigenasa (ido).
NZ746554A (en) Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith
MX2015011374A (es) Inhibidores de indolamina 2,3-dioxigenasa (ido).
PH12019500957A1 (en) Selective inhibitor of exon 20 insertion mutant egfr
MX2019011506A (es) Inhibicion de cinasa 1 de punto de control (chk1) para el tratamiento de cancer.
PH12018502314A1 (en) Enhancer of zeste homolog 2 inhibitors
MX2017015923A (es) Inhibidores de indolamina-2,3-dioxigenasa (ido).
SG11201901815WA (en) Anti-tumor agent, anti-tumor effect enhancer, and anti-tumor kit
PH12016502130A1 (en) Novel pyrrolopyrimidine compound or salt thereof, pharmaceutical composition containing same, especially agent for prevention and/or treatment of tumors etc based on nae inhibitory effect
ZA202301066B (en) Phthalazine derivatives as inhibitors of parp1, parp2 and/or tubulin useful for the treatment of cancer
NZ756012A (en) Therapeutic inhibitors of the reverse mode of atp synthase
MX2020012782A (es) Inhibidor de ccr5 para el uso en el tratamiento de cancer.
MX388409B (es) Composiciones y metodos para tratar canceres.
MX2018002612A (es) Composicion farmaceutica para tumor que tiene mutacion de isocitrato deshidrogenada, agente antitumoral y uso del mismo.
MX2018002611A (es) Agente antitumoral para cancer del tracto biliar y metodo para tratar cancer del tracto biliar.
MX2020013805A (es) Derivados de piridopirimidinona para uso como inhibidores de axl.
NZ738247A (en) 4-(3-pyrazolylamino)-benzimidazole compounds and their use as jak1 inhibitors
MX387059B (es) Compuestos de benzo-n-hidroxi amida que tienen actividad antitumoral.